trial

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

NCTId NCT03230864
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 119 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2018-12-23
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
119 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2017-07-20
Primary completion
2018-12-23
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Lu AF35700RisperidoneOlanzapine

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

41 total
San Diego, United StatesAtlanta, United StatesChicago, United StatesFall River, United StatesWorcester, United StatesAnn Arbor, United StatesKalamazoo, United StatesSt Louis, United StatesOmaha, United StatesSalt Lake City, United StatesKardzhali, BulgariaNovi Iskar, Bulgaria

Linked catalysts

1
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Trea — primary completion2018-12-23

Facts & assertions

4 sourced
Enrollment
119
Phase
PHASE3
Primary Completion Date
2018-12-23
Status
TERMINATED
relationships
The graph out of here
drug
Lu AF35700
drug
Risperidone
drug
Olanzapine
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia, Treatment-Resistant
indication
Treatment-resistant Schizophrenia
indication